Education
About Us
Working with TipRanks
Follow Us
Ironwood Pharmaceuticals (DE:I76)
:I76
I76 Stock Chart & Stats
€1.69
-€0.16(-3.60%)
At close: 4:00 PM EST
€1.69
-€0.16(-3.60%)
Day’s Range― - ―
52-Week Range€0.48 - €4.52
Previous CloseN/A
Volume0.00
Average Volume (3M)1.27K
Market Cap
€269.85M
Enterprise Value€632.64M
Total Cash (Recent Filing)€140.41M
Total Debt (Recent Filing)€213.24M
Price to Earnings (P/E)―
Beta0.12
Next Earnings
Feb 12, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.20
Shares Outstanding162,434,130
10 Day Avg. Volume1,370
30 Day Avg. Volume1,269
Financial Highlights & Ratios
PEG Ratio-8.00
Price to Book (P/B)-2.34
Price to Sales (P/S)2.01
P/FCF Ratio6.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformanceLinzess revenues of $248M for 2Q25 appear on track to meet guidance of $800-850M and reflect normalization of gross-to-net accounting fluctuations.
ProfitabilityIRWD also raised FY25 Adjusted EBITDA guidance by ~$20M to $105M+ driven by expectation of lower commercial spend related to the Apra launch.
Revenue GrowthPrescription demand growth continues to be strong with IRWD highlighting 8% y/y volume growth in 1Q25.
Bears Say
Debt ChallengesThe high debt load and delay in apraglutide's revenue contribution mean there will likely be no meaningful revenue contribution until after Linzess' loss of exclusivity and debt maturity.
Regulatory SetbacksThe launch of Apraglutide has been delayed to 2029, reflecting setbacks in the drug's development and approval process.
Stock OutlookThe price target has been reduced from $3.00 to $1.00, indicating a more cautious outlook on the stock.
Ironwood Pharma News
I76 FAQ
What was Ironwood Pharmaceuticals’s price range in the past 12 months?
Ironwood Pharmaceuticals lowest stock price was €0.48 and its highest was €4.52 in the past 12 months.
What is Ironwood Pharmaceuticals’s market cap?
Ironwood Pharmaceuticals’s market cap is €269.85M.
When is Ironwood Pharmaceuticals’s upcoming earnings report date?
Ironwood Pharmaceuticals’s upcoming earnings report date is Feb 12, 2026 which is in 92 days.
How were Ironwood Pharmaceuticals’s earnings last quarter?
Ironwood Pharmaceuticals released its earnings results on Nov 10, 2025. The company reported €0.199 earnings per share for the quarter, beating the consensus estimate of €0.092 by €0.107.
Is Ironwood Pharmaceuticals overvalued?
According to Wall Street analysts Ironwood Pharmaceuticals’s price is currently Overvalued.
Does Ironwood Pharmaceuticals pay dividends?
Ironwood Pharmaceuticals does not currently pay dividends.
What is Ironwood Pharmaceuticals’s EPS estimate?
Ironwood Pharmaceuticals’s EPS estimate is 0.03.
How many shares outstanding does Ironwood Pharmaceuticals have?
Ironwood Pharmaceuticals has 162,434,130 shares outstanding.
What happened to Ironwood Pharmaceuticals’s price movement after its last earnings report?
Ironwood Pharmaceuticals reported an EPS of €0.199 in its last earnings report, beating expectations of €0.092. Following the earnings report the stock price went up 33.721%.
Which hedge fund is a major shareholder of Ironwood Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:I76
Ironwood Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
DE:I76 Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $11.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-58.79%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.31%
Trailing 12-Months
Company Description
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
I76 Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Dynavax
―
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Evotec AG
―
Collegium Pharmaceutical
―
Options Prices
Currently, No data available
---